Background
GBR 1342 OVERVIEW
 GBR 1342 is a novel CD3xCD38 bispecific antibody engineered (using the Glenmark Bispecific Engagement by Antibodies based on the T cell receptor [BEAT®] platform) to direct T cells to CD38-expressing myeloma cells by engaging the CD3 molecule on T lymphocytes and the CD38 antigen on tumor cells, thereby killing the bound target cells through redirected lysis (Figure 1)  Includes a single chain, variable fragment arm with anti-CD38 specificity and a fragment antigen binding (Fab) arm with anti-CD3ε specificity  GBR 1342 has full antibody-like pharmacokinetics (PK) with a long elimination half-life of approximately 110 hours (in rats), which is similar to IgG and therefore permits intermittent dosing  GBR 1342 has low immunogenicity potential 
KEY FINDINGS
 In redirected lysis (RDL) assays, GBR 1342 demonstrated greater potency versus daratumumab on all cell lines tested, suggesting the redirecting ability of GBR 1342 affords more rapid and efficient T cell cytotoxic activity (Figure 3 )  These data suggest that the unique mechanism of action of GBR 1342 may afford superior anti-tumor activity to patients with multiple myeloma compared with conventional CD38-targeting therapies (eg, daratumumab 1 ) 
